A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Boris Juelg, MD, PhD
Massachusetts General Hospital
Principal Investigator - Julie McElrath, MD, PhD
Seattle HIV Vaccine Trials Unit
Principal Investigator - Omu Anzala, MBChB, PhD
Kenya AIDS Vaccine Initiative - Institute of Clinical Research (KAVI-ICR)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Kenya Aids Vaccine Initiative
Nairobi, Kenya
- Mgh
Boston, Massachusetts, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Dec 2018
- Primary completion
- 21 Mar 2023
- Completion
- 11 Jul 2023
- Last update posted
- 14 Dec 2023
- Registered enrollment
- 61
- Registry id
- NCT03699241
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.